December 20, 2010
RESEARCH TRIANGLE PARK, N.C. (December 20, 2010) — Metabolon, Inc., the leader in metabolomics, biomarker discovery and analysis, announces the publication of “Novel Role of Adenosine Signaling in Sickle Cell Disease”, in Nature Medicine. Application of non-targeted biochemical profiling (metabolomics) to a mouse model of sickle cell disease (SCD) revealed a detrimental role of adenosine signaling in SCD and suggested novel therapeutic targets. The study was carried out in collaboration with The University of Texas Health Science Center at Houston.
Sickle cell disease (SCD), a devastating inherited blood disorder, is caused by a point mutation in the ß-globin chain of hemoglobin. Despite knowledge of the molecular defect associated with sickle hemoglobin (HbS), preventative approaches or mechanism-specific treatment options for the disease are lacking. Metabolon’s biochemical profiling technology was used to understand the molecular events involved in the pathogenesis of red blood cell sickling, so that novel therapeutic strategies to treat this disease can be developed. Adenosine was discovered to be highly elevated in the blood of SCD transgenic mice. Lowering adenosine concentrations significantly reduced sickling, hemolysis and multiple organ damage in the mice. Thus, these findings demonstrate the power of Metabolon’s global profiling technology to understand the underlying disease mechanism and to identify novel therapeutic possibilities to treat and prevent damage resulting from SCD.
Copies of the paper can be accessed at: http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.2280.html
About Metabolon
Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com or contact Matt Zaske mzaske@metabolon.com at (919) 595-2200.
November 30, 2010
RESEARCH TRIANGLE PARK, N.C. (November 30, 2010) — Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announces the publication of “Metabolic Footprint of Diabetes: A Multiplatform Metabolomics Study in an Epidemiological Setting” in PLoS ONE.
Data from Metabolon’s non-targeted biochemical profiling platform was combined with data collected from targeted metabolomics platforms to identify metabolic signatures that are associated with Type 2 diabetes. The proof of concept study illustrates the value of using metabolomics to identify biochemical pathways affected by Type 2 diabetes. The authors show that functional metabolomics can contribute to the development of a more sophisticated classification of the disease and lead to optimized diagnosis and treatment options.
Copies of the paper can be accessed from PLoS ONE: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0013953
About Metabolon
Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com or contact Matt Zaske mzaske@metabolon.com at (919) 595-2200.
October 20, 2010
RESEARCH TRIANGLE PARK, N.C. (October 20, 2010) — Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announced today the grant of US Patent 7,807,138 entitled “Biomarkers of Metabolic Responses to Hepatic Drugs”. The USPTO awarded the patent to Metabolon on October 5, 2010. This is the 13th patent issued to Metabolon and the second in its portfolio of biomarker patents.
The patent claims cover biomarker combinations for determining the efficacy of PPAR-affecting drugs on a subject. PPARs are nuclear receptors that are activated by lipids and play critical roles in the catabolism and storage of fatty acids. Since PPAR modulation can normalize metabolic dysfunctions and reduce some cardiovascular risk factors associated with type 2 diabetes (T2D) the receptors are valuable pharmacological targets. Thiazolidinediones are PPARgamma agonists and insulin sensitizers that improve insulin resistance in T2D patients. Fibrates are PPARalpha agonists that can correct dyslipidemia. However, both classes of drugs have associated detrimental side effects and on-going research is focused on developing new drugs that minimize the harmful effects while maximizing the protective effects. The newly patented biomarkers were developed to facilitate the discovery and development of novel PPAR agonists with enhanced efficacy and reduced toxicity.
Metabolon is the exclusive license holder of the Daouk-Kristal patent family which is comprised of early, pioneering patents and patent applications which provide fundamental IP in the field of metabolomics. Metabolon’s previously issued patents include the use of metabolomics for determining biomarkers for disease, including cancer, metabolic disorders, and neurological disorders such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, depression and schizophrenia, and for evaluating chemical agents for therapeutic effects and toxicity. Metabolon also owns patents relating to software designed for analyzing metabolomics data.
About Metabolon
Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com or contact Matt Zaske atmzaske@metabolon.com or (919) 595-2200.
October 19, 2010
RESEARCH TRIANGLE PARK, N.C. (October 19, 2010)—Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announces the online publication of “Organization of GC/MS and LC/MS Metabolomics Data into Chemical Libraries” in the Journal of Cheminformatics. The article describes the automated identification of individual compounds based on the biological variability in compound concentrations across multiple samples. A US patent, US7,561,975, has been issued to Metabolon on the methodology described in the paper.
To access the article please click here.
About Metabolon
Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com or contact Matt Zaske atmzaske@metabolon.com or (919) 595-2200.
October 15, 2010
RESEARCH TRIANGLE PARK, N.C. (October 15, 2010)—Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announces the publication of “Metabolomic Profiling Reveals Biochemical Pathways and Biomarkers Associated with Pathogenesis in Cystic Fibrosis Cells”, in the Journal of Biological Chemistry (2010, Vol. 285, No. 40, Pages 30516-30522). The article describes the application of non-targeted biochemical profiling (metabolomics) to study the biochemical changes in human lung epithelial cell lines of cystic fibrosis (CF) patients. The study was carried out in collaboration with the Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), a nonprofit subsidiary of the Cystic Fibrosis Foundation, and CF researchers from the University of Pittsburgh funded by CFFT.
The identification of the cystic fibrosis transmembrane conductance regulator (CFTR) gene has lead to many genetic and molecular biology studies which have aided our understanding of the effects of gene mutations on the CFTR protein. Yet, how the CFTR defects lead to downstream biological changes and the resulting CF clinical symptoms remains unclear. In the JBC report, the investigators used metabolomics to gain an initial understanding of the global biochemical alterations in CF primary lung epithelial cells. The authors measured changes in glucose, sorbitol and pentose phosphate metabolism that could serve to exacerbate CF-associated oxidative stress as well as other metabolic changes that suggest altered purinergic signaling.
Copies of the paper can be accessed: Click Here.
About Metabolon
Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com or contact Matt Zaske atmzaske@metabolon.com or (919) 595-2200.
October 13, 2010
RESEARCH TRIANGLE PARK, N.C. (October 13, 2010)—Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announces the publication of “Ablation of the Locus Coeruleus (LC) Increases Oxidative Stress in Tg-2576 Transgenic But Not Wild-type Mice” in the International Journal of Alzheimer Disease. The paper examines the role of the LC on markers of oxidative stress in transgenic mice and was carried out as a collaboration among scientists at Pfizer, Proteostasis Therapeutics, the University of Dundee, Duke University and Metabolon. The paper is co-authored by Orest Hurko, Kurt Boudonck, Cathleen Gonzalez, J. Steve Jacobsen, Peter H. Reinhart, Crowther Daniel, Zoe A. Hughes.
Previous research in this area suggested that differences in inflammatory response observed in humans with Alzheimer disease and mouse models reflect a discrepancy in the state of the LC, the major site of norepinephrine synthesis in the brain. LC degeneration is an early change in human Alzheimer disease, but it is preserved in transgenic mouse models of Alzheimer disease. The authors use a non-targeted metabolomic approach to examine the effects of ablating the LC on oxidative stress and intermediary metabolism. Mice transgenic for beta-amyloid (Tg2576Aß) in which the LC had been ablated showed greater concordance with human Alzheimer disease, including increased oxidative stress and altered energy metabolism. The results support the proposal that LC degeneration may contribute to key pathophysiological features of Alzheimer disease, and extend the hypothesis from inflammation to oxidative stress and altered carbohydrate metabolism. Moreover, transgenic mice with an LC ablation may provide a more congruent model for human Alzheimer disease than transgenic mice with intact LC.
Copies of the paper can be accessed through the International Journal of Alzheimer Disease here
About Metabolon
Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com or contact Matt Zaske mzaske@metabolon.com at (919) 595-2200.
September 22, 2010
RESEARCH TRIANGLE PARK, N.C. (September 22, 2010)—Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announces the publication of “Assessment of Dentifrice on Periodontal Disease Biomarkers in Gingival Crevicular Fluid”, in the Journal of Periodontology (2010, Vol. 81, No. 9, Pages 1273-1279). The article reports the results of a biomarker validation study carried out in collaboration with co-authors Virginia M. Barnes and colleagues of Colgate-Palmolive, a global leader in oral care. Periodontal disease, described as inflammation of the gums, is among the most common infectious diseases. Triclosan, the active ingredient in Colgate Total (CT), is a proven therapeutic agent against gingivitis. CT is the only FDA approved dentifrice for the treatment of gingivitis.
The study follows previous research by Dr. Barnes and collaborators at Colgate-Palmolive Company which used Metabolon’s patented global metabolomic profiling platform to identify candidate biomarkers in gingival crevicular fluid samples from subjects with chronic periodontitis. In this latest report, the biomarkers associated with gingivitis and periodontitis identified in the previous study, were validated as sensitive indicators for periodontal diseases. The levels of inosine, lysine, putrescine and xanthine correlated with the therapeutic effects of brushing with CT, a triclosan-containing dentrifice, against gingivitis and provided biochemical confirmation that CT can provide therapeutic improvement against gingivitis. These four biomarkers were significantly altered before observable clinical changes suggesting they could be useful for rapidly assessing clinical efficacy of anti-gingivitis products.
Copies of the paper can be accessed through the Journal of Periodontology at: www.joponline.org/doi/abs/10.1902/jop.2010.100070?journalCode=jop
About Metabolon
Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com or contact Matt Zaske mzaske@metabolon.com at (919) 595-2200.
September 13, 2010
RESEARCH TRIANGLE PARK, N.C. (September 13, 2010) — Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announced today the grant of US Patent 7,781,160 entitled “Biomarkers Related to Metabolic Age and Methods Using the Same”. The USPTO awarded the patent to Metabolon on August 24, 2010. This is the 12th patent issued to Metabolon.
As more information regarding the impact of nutrition on health-related issues becomes available and as the population ages, interest in health and nutrition has increased. The metabolism of an individual changes with age. Until recently the ability to monitor metabolite changes has been limited to targeted assays. With the development of metabolomics analysis, changes in metabolites can now be monitored globally in a non-targeted manner. This metabolomic approach allows a metabolic profile to be determined for a group or an individual. The patented invention provides biomarkers and methods to determine the metabolic age of an individual. The ability to determine the metabolite levels of an individual and classify the resulting metabolic profile as positive or negative and then to provide guidance as to how to improve a negative profile will have beneficial effects on the health of an individual.
Metabolon is the exclusive license holder of the Daouk-Kristal patent family which is comprised of early, pioneering patents and patent applications which provide fundamental IP in the field of metabolomics. Metabolon’s previously issued patents include the use of metabolomics for determining biomarkers for disease, including cancer, metabolic disorders, and neurological disorders such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, depression and schizophrenia, and for evaluating chemical agents for therapeutic effects and toxicity. Metabolon also owns patents relating to software designed for analyzing metabolomics data.
About Metabolon
Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com or contact Matt Zaske at mzaske@metabolon.com or 919-595-2200.
July 13, 2010
RESEARCH TRIANGLE PARK, N.C. (July 13, 2010)—Metabolon, Inc., the leader in global metabolism through biomarker discovery and analysis, today announces the publication of “Ethylene Glycol Monomethyl Ether-Induced Toxicity is Mediated through the Inhibition of Flavoprotein Dehydrogenase Enzyme Family”, in the journal Toxicological Sciences on July 8, 2010. The paper was co-authored by Dr. Makoto Takei and colleagues at Daiichi-Sankyo in collaboration with Metabolon scientists.
Ethylene glycol monomethyl ether (EGME) is a widely used industrial solvent that causes hematological, neurological, immunological and reproductive damage as well as other adverse effects in humans and other mammals. Tissues and organs with rapidly dividing cells and high rates of metabolism, such as the testes and thymus, are especially sensitive to EGME. Metabolon’s biochemical profiling technology was used to gain a mechanistic understanding of EGME’s effects on metabolism. The untargeted metabolomic analysis of serum, urine, liver and testes collected from EGME-treated rats revealed biochemical profiles similar to biochemical signatures observed in humans with multiple acyl-CoA dehydrogenase deficiency (MADD), an inborn error of metabolism. Based on the biochemical analysis the authors propose the mode of action of EGME-induced toxicity is mediated through the inhibition of primary flavoprotein dehydrogenases.
Copies of the paper can be accessed through Toxicological Sciences by clicking
here or, alternatively, copy and pasting the link below into your web browser: http://toxsci.oxfordjournals.org/cgi/reprint/kfq211ijkey=ouzQ8rGHBcz28KS&keytype=ref
About Metabolon
Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com or contact Matt Zaske at mzaske@metabolon.com or (919) 595-2200.
July 2, 2010
RESEARCH TRIANGLE PARK, N.C. (July 02, 2010)— Metabolon, Inc., the leader in global metabolism, biomarker discovery and analysis, announces the publication of “Metabolomics in premature labor: a novel approach to identify patients at risk for preterm delivery”, in The Journal of Maternal-Fetal and Neonatal Medicine.
The study, carried out in collaboration with co-authors Dr. Roberto Romero and colleagues of the NICHD, NIH, and DHHS, aimed to identify prognostic and diagnostic biomarkers of preterm delivery in women with spontaneous preterm labor (PTL) and intact membranes. Spontaneous preterm labor does not always lead to preterm delivery and the accurate and rapid identification of the risk of preterm delivery to pregnant women with PTL is needed for physicians to make immediate patient management decisions. The report describes the identification of biomarkers for PTL and delivery and concludes that the risk of preterm delivery, in the presence or absence of infection and inflammation, can be assessed by metabolic profiling of amniotic fluid. In addition, the report presents a preliminary draft of the human amniotic fluid metabolome from women with PTL that shows biochemical intermediates of human metabolism as well as xenobiotics such as salicylamide and bacterial products can be measured in human amniotic fluid.
Copies of the paper can be accessed through the Journal of Maternal-Fetal and Neonatal Medicine by clicking here or, alternatively, copy and pasting the link below into your web browser: http://informahealthcare.com/doi/abs/10.3109/14767058.2010.482618
About Metabolon
Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com or contact Matt Zaske mzaske@metabolon.com at (919) 595-2200.
June 16, 2010
RESEARCH TRIANGLE PARK, N.C. (June 16, 2010)—Metabolon, Inc., the leader in metabolomics-based biomarker discovery and analysis, today announced the publication of research that identified a novel, early biomarker for insulin resistance and glucose intolerance in a nondiabetic population. Co-authored by physicians and scientists from EGIR (European Group for the Study of Insulin Resistance) and Metabolon, the paper, “alpha-hydroxybutyrate Is an Early Biomarker of Insulin Resistance and Glucose Intolerance in a Nondiabetic Population”, appears on the PLoS One website (www.plosone.org) (doi:10.1371/journal.pone.0010883 (May 28th 2010)). Please click here for the article.
Metabolon’s biochemical profiling technology was deployed on plasma samples from 399 nondiabetic subjects from EGIR’s large prospective RISC (Relationship between Insulin Sensitivity and Cardiovascular Disease) cohort, representing a broad spectrum of insulin sensitivity and glucose tolerance. Alpha-hydroxybutyrate was the statistically top-ranked biochemical for classifying subjects as insulin resistant or insulin sensitive. Commenting on the study results, senior RISC author Ele Ferrannini, M.D. summarized, “From this unbiased, biochemical screen, alpha-hydroxybutyrate, an intermediate metabolite of amino acid metabolism, was the strongest biochemical that marks as a single metabolic fingerprint of in vivo human insulin resistance.”
Insulin resistance is an abnormal metabolic condition and a recognized clinical predictor of type 2 diabetes and cardiovascular disease, with association with obesity, certain cancers, and other metabolic diseases. Metabolon is currently developing a fasted plasma diagnostic test for insulin resistance to allow physicians to more accurately assess their at-risk patient population. As described in the article, alpha-hydroxybutyrate and other metabolites have been identified as a metabolic signature of insulin resistance.
About Metabolon
Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com or contact Matt Zaske mzaske@metabolon.com at (919) 595-2200.
About EGIR
The EGIR group was formed several years ago by a group of investigators from different research backgrounds - epidemiology, endocrinology, basic science, public health - interested in insulin resistance. The first combined activity of the group was a data pooling project from euglycemic hyperinsulinemic clamp experiments performed in 21 centers across Europe. EGIR is managed by a Steering Committee and its scientific activities are managed by a separate Project Management Board. In 2001 the EGIR project Relationship between Insulin Sensitivity and Cardiovascular Disease (RISC) was awarded funding by the EU 5th Framework to carry out a project examining the effects of insulin resistance in healthy people (without diabetes or hypertension). The project started on 1 February 2002 and the 3-year follow up examinations were completed in December 2007. For more information about EGIR, please visit www.egir.org.
May 13, 2010
RESEARCH TRIANGLE PARK, N.C. (May 13, 2010)— Metabolon, Inc. announces a study published in the Metabolism Journal due for release in the paper on April 26, 2010, by Satish C. Kalhan.
Metabolon, Inc., the leader in global metabolism, biomarker discovery and analysis, studied plasma profiles from subjects with nonalcoholic fatty liver disease (NAFLD). Using Metabolon’s patented global metabolomic profiling platform, the study, authored by Satish C. Kalhan and his collaborators at the Cleveland Clinic and Case Western Reserve University School of Medicine and with scientists from Metabolon, identified a panel of potential noninvasive biomarkers in NAFLD and Nonalcoholic Steatohepatitis (NASH). The results represent both a significant step in understanding the disease and for the development of therapeutic interventions.
Nonalcoholic steatohepatitis (NASH) is described as inflammation of the liver associated with the accumulation of fat in the liver. NAFLD and NASH occur in individuals who do not consume excessive amounts of alcohol, yet has similarities in what can be seen in liver disease with an excessive intake of alcohol.
Copies of the paper can be accessed through ScienceDirect at: www.metabolismjournal.com.
About Metabolon
Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit
www.metabolon.com.
###
March 31, 2010
RESEARCH TRIANGLE PARK, N.C. (March 31, 2010)—Metabolon, Inc., the leader in global metabolism through biomarker discovery and analysis, announced today the grant of US Patent 7,682,783 and US Patent 7,682,784 entitled “Methods for Drug Discovery, Disease Treatment and Diagnosis Using Metabolomics”. The USPTO awarded the patents to Metabolon on March 23, 2010. The issued claims in the new patents are for uses of metabolomics to identify diagnostic biomarkers for depression and schizophrenia by profiling classes of metabolites in a sample.
The innovations provide means to identify novel metabolite biomarkers for depression or schizophrenia by profiling the biochemicals, such as sugars, nucleotides, fatty acids, amino acids and other small molecules, in patient samples and then comparing the profiles with reference profiles. These profiles and biomarkers can be developed into diagnostic tests for these mental disorders. In addition, the biomarkers can be used in drug development to monitor clinical trials.
Metabolon is the exclusive license holder of the Daouk-Kristal patent family which is comprised of early, pioneering patents and patent applications which provide fundamental IP in the field of metabolomics. The ‘783 and ’784 patents are the seventh and eighth patents to issue from the Daouk-Kristal family. Metabolon’s previously issued patents include the use of metabolomics for determining biomarkers for disease, including cancer, metabolic disorders, and neurological disorders such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, depression and schizophrenia, and for evaluating chemical agents for therapeutic effects and toxicity. Metabolon also owns patents relating to software designed for analyzing metabolomics data.
About Metabolon
Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com.
###
For more information:
Matt Zaske
Metabolon, Inc.
919.595.2200
mzaske@metabolon.com
www.metabolon.com
January 13, 2010
RESEARCH TRIANGLE PARK, N.C. (January 13, 2010)—Metabolon, Inc., the leader in global metabolism through biomarker discovery and analysis, today announced that it was awarded US Patent 7,635,556 “Methods for Drug Discovery, Disease Treatment and Diagnosis Using Metabolomics” by the United States Patent and Trademark Office on December 22, 2009. This is the sixth patent to issue from the fundamental Daouk-Kristal “metabolomics methods” patent family and the fourth one in this portfolio to be granted in 2009.
The ‘556 patent is directed to identifying small molecules that are affected by a drug or a toxin using metabolomics. It provides a method to evaluate chemical agents for drug effects and toxicity, thereby facilitating pre-clinical and clinical drug development activities. The patent extends Metabolon’s IP related to the use of metabolomics beyond disease biomarker discovery into uses of metabolomics for drug discovery and development.
Metabolon is the exclusive license holder of the Daouk-Kristal patent family which is comprised of early, pioneering patents and patent applications which provide fundamental IP in the field of metabolomics. Metabolon’s previously issued patents include the use of metabolomics for determining biomarkers for disease, including cancer, metabolic disorders, and neurological disorders such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, depression and schizophrenia. Metabolon also owns patents relating to software designed for analyzing metabolomics data.
About Metabolon
Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com.